Sinopharm Group Co Ltd (1099.HK) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sinopharm Group Co Ltd announces further acquisition of 14 pct equity interest in Sichuan Medicine


Friday, 15 Aug 2014 10:32am EDT 

Sinopharm Group Co Ltd:Refers to the announcement made earlier, in relation to the company’s acquisition of 17.5 pct equity interest in Sichuan Medicine from Sichuan Sanxin Co and its further acquisition of 17.5 pct equity interest in Sichuan Medicine from Sichuan Investment Fund, respectively.Says it further entered into an equity transfer agreement with Sichuan Furun in respect of the acquisition of 14 pct equity interest in Sichuan Medicine through the open tender process at the Southwest United Equity Exchange at a consideration of 202,490,400 yuan.Upon completion of the transaction under the equity transfer agreement, the company’s equity interest in Sichuan Medicine will be increased to 49 pct, while the remaining 51 pct equity interest in Sichuan Medicine is held by Sichuan Medicine Group. 

Related Company News

Company Quote

36.95
0.95 +2.64%
3:59am EDT